Isabelle C, Boles A, McConnell K, Keller R, Burzinski R, Hutchins Z
Leukemia. 2025; .
PMID: 40057636
DOI: 10.1038/s41375-025-02551-4.
Zubiaur M, Terron-Camero L, Gordillo-Gonzalez F, Andres-Leon E, Barroso-Del Jesus A, Canet-Antequera L
Front Immunol. 2025; 16:1441981.
PMID: 39995666
PMC: 11847871.
DOI: 10.3389/fimmu.2025.1441981.
Bei J, Sun Z, Fu R, Huang X, Huang J, Luo Y
J Hepatocell Carcinoma. 2024; 11:2453-2470.
PMID: 39679070
PMC: 11646373.
DOI: 10.2147/JHC.S492420.
Huo M, Adeerjiang Y, Abulitipu A, Khan U, Li X, Zhang L
Front Oncol. 2024; 14:1325575.
PMID: 39534095
PMC: 11554530.
DOI: 10.3389/fonc.2024.1325575.
Hamada M, Nishiyama K, Nomura R, Akitomo T, Mitsuhata C, Yura Y
Heliyon. 2024; 10(20):e39284.
PMID: 39497974
PMC: 11533578.
DOI: 10.1016/j.heliyon.2024.e39284.
Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?.
Anvar M, Rashidan K, Arsam N, Rasouli-Saravani A, Yadegari H, Ahmadi A
Cancer Cell Int. 2024; 24(1):355.
PMID: 39465401
PMC: 11514949.
DOI: 10.1186/s12935-024-03525-9.
Transcription factor TCF1 binds to RORγt and orchestrates a regulatory network that determines homeostatic Th17 cell state.
Mangani D, Subramanian A, Huang L, Cheng H, Krovi S, Wu Y
Immunity. 2024; 57(11):2565-2582.e6.
PMID: 39447575
PMC: 11614491.
DOI: 10.1016/j.immuni.2024.09.017.
Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events.
Haugh A, Daud A
J Clin Invest. 2024; 134(20).
PMID: 39403930
PMC: 11473163.
DOI: 10.1172/JCI184310.
Strategies for Improving CAR T Cell Persistence in Solid Tumors.
Wittling M, Cole A, Brammer B, Diatikar K, Schmitt N, Paulos C
Cancers (Basel). 2024; 16(16).
PMID: 39199630
PMC: 11352972.
DOI: 10.3390/cancers16162858.
Bioinformatics analysis of the tumor microenvironment in melanoma - Constructing a prognostic model based on CD8+ T cell-related genes: An observational study.
He Z, Chen M, Luo Z
Medicine (Baltimore). 2024; 103(32):e38924.
PMID: 39121331
PMC: 11315512.
DOI: 10.1097/MD.0000000000038924.
Targeting p97-Npl4 interaction inhibits tumor T cell development to enhance tumor immunity.
Nie P, Cao Z, Yu R, Dong C, Zhang W, Meng Y
Nat Immunol. 2024; 25(9):1623-1636.
PMID: 39107403
DOI: 10.1038/s41590-024-01912-y.
The Complex Dysregulations of CD4 T Cell Subtypes in HIV Infection.
Tolomeo M, Cascio A
Int J Mol Sci. 2024; 25(14).
PMID: 39062756
PMC: 11276885.
DOI: 10.3390/ijms25147512.
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia.
Gamal W, Mediavilla-Varela M, Uriepero-Palma A, Pinilla-Ibarz J, Sahakian E
Int J Mol Sci. 2024; 25(12).
PMID: 38928031
PMC: 11203624.
DOI: 10.3390/ijms25126324.
IRX5's influence on macrophage polarization and outcome in papillary thyroid cancer.
Qin L, Chen C, Gui Z, Jiang Y
Front Oncol. 2024; 14:1399484.
PMID: 38868535
PMC: 11167072.
DOI: 10.3389/fonc.2024.1399484.
Preservation of naive-phenotype CD4+ T cells after vaccination contributes to durable immunity.
Pan Y, Bartolo L, Xu R, Patel B, Zarnitsyna V, Su L
JCI Insight. 2024; 9(14).
PMID: 38861490
PMC: 11383171.
DOI: 10.1172/jci.insight.180667.
Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD.
Wang Y, Ullah M, Waltner O, Bhise S, Ensbey K, Schmidt C
J Clin Invest. 2024; 134(11).
PMID: 38828727
PMC: 11142741.
DOI: 10.1172/JCI170125.
Th17-to-Tfh plasticity during periodontitis limits disease pathology.
McClure F, Wemyss K, Cox J, Bridgeman H, Prise I, King J
J Exp Med. 2024; 221(8).
PMID: 38819409
PMC: 11143381.
DOI: 10.1084/jem.20232015.
Differentiation marker-negative CD4 T cells persist after yellow fever virus vaccination and contribute to durable memory.
Pan Y, Bartolo L, Xu R, Patel B, Zarnitsyna V, Su L
bioRxiv. 2024; .
PMID: 38559113
PMC: 10979963.
DOI: 10.1101/2024.03.11.584523.
Gut Microbiome-Related Anti-Inflammatory Effects of Aryl Hydrocarbon Receptor Activation on Inflammatory Bowel Disease.
Moutusy S, Ohsako S
Int J Mol Sci. 2024; 25(6).
PMID: 38542367
PMC: 10970487.
DOI: 10.3390/ijms25063372.
Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy.
Xue G, Li X, Kalim M, Fang J, Jiang Z, Zheng N
Cancer Cell. 2024; 42(5):780-796.e6.
PMID: 38518774
PMC: 11756590.
DOI: 10.1016/j.ccell.2024.03.001.